Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer.
Dang CT, D'Andrea GM, Moynahan ME, Dickler MN, Seidman AD, Fornier M, Robson ME, Theodoulou M, Lake D, Currie VE, Hurria A, Panageas KS, Norton L, Hudis CA.
Dang CT, et al. Among authors: d andrea gm, lake d.
Clin Cancer Res. 2004 Sep 1;10(17):5754-61. doi: 10.1158/1078-0432.CCR-04-0634.
Clin Cancer Res. 2004.
PMID: 15355903
Clinical Trial.